,Chapter01:3Information3Sources,3Regulatory3Agencies,3Drug3Legislation,3and3Prescription3Wri
ting
Haveles:3Applied3Pharmacology3for3the3Dental3Hygienist,39th3Edition
MULTIPLE3CHOICE
1. Knowledge3of3pharmacology3aids3the3dental3professional3in
a. obtaining3a3patient’s3health3history.
b. administering3drugs3in3the3office.
c. handling3emergency3situations.
d. selection3of3a3nonprescription3medication.
e. All3of3the3above.
ANS:3 E
All3of3the3choices3are3true.3Because3many3of3our3patients3are3being3treated3with3drugs,3knowledge3of
3pharmacology3helps3in3understanding3and3interpreting3patients’3responses3to3health3history3questions
.3Knowledge3of3the3therapeutic3and3adverse3effects3of3medications3obviously3helps3in3their3proper3ad
ministration3in3the3office.3Emergency3situations3may3be3caused3by3drugs3or3treated3by3drugs;3thus,3k
nowledge3of3pharmacology3is3of3great3help,3especially3because3a3rapid3response3is3sometimes3requir
ed.3A3clear3understanding3of3the3concepts3of3drug3action,3drug3handling3by3the3body,3and3drug3intera
ctions3will3allow3the3dental3practitioner3to3make3proper3judgments3and3grasp3the3concepts3relevant3to
3new3drug3therapies3on3the3market.
DIF: Application
REF:3 Role3of3the3Dental3Hygienist3(Medication/Health3History),3Role3of3the3Dental3Hygienist3(Medicati
on3Administration),3Role3of3the3Dental3Hygienist3(Emergency3Situations),3Role3of3the3Dental3Hygienist3(
Nonprescription3Medication)3|3pp.32-3 OBJ: 1
TOP:3 NBDHE,36.0.3Pharmacology
2. Which3of3the3following3statements3is3true3regarding3planning3appointments?
a. Whether3or3not3patients3are3taking3medication3for3systemic3diseases3is3of3littl
e
consequence3in3the3dental3office.
b. Asthmatic3patients3should3have3dental3appointments3in3the3morning.
c. Diabetic3patients3usually3have3fewer3problems3with3a3morning3appointment 3c
ompared3with3afternoon3appointments.
d. Both3B3and3C3are3true.
ANS:3 D
Asthmatic3patients3who3experience3dental3anxiety3should3schedule3their3appointments3when3they3are3
not3rushed3or3under3pressure3early3in3the3morning.3Diabetic3patients3usually3have3relatively3fewer3pr
oblems3with3a3morning3appointment.3Patients3taking3medication3for3systemic3diseases3may3require3s
pecial3handling3in3the3dental3office.
DIF: Comprehension
REF:3 Role3of3the3Dental3Hygienist3(Appointment3Scheduling)3|3p.3
33OBJ:3 1 TOP:3 NBDHE,36.0.3Pharmacology
,3. Nutritional3or3herbal3supplements
a. carry3the3U.S.3Food3and3Drug3Administration3(FDA)3approval3for3disease3states
.
b. are3not3drugs.
c. can3cause3adverse3effects.
d. will3not3interact3with3other3drugs3the3patient3may3be3taking.
ANS:3 C
Nutritional3or3herbal3supplements3are3quite3capable3of3causing3adverse3effects.3The3majority3of3nutritio
nal3or3herbal3supplements3do3not3carry3FDA3approval3for3treating3disease3states.3These3supplements3ar
e3drugs3and3can3cause3adverse3effects3and3interact3with3different3drugs.
DIF: Comprehension
REF:3 Role3of3the3Dental3Hygienist3(Nutritional3or3Herbal3Supplements)3|3p.
333OBJ:3 1 TOP:3 NBDHE,36.0.3Pharmacology
4. Which3type3of3drug3name3usually3begins3with3a3lowercase3letter?
a. Brand3name
b. Code3name
c. Generic3name
d. Trade3name
ANS:3 C
Before3any3drug3is3marketed,3it3is3given3a3generic3name3that3becomes3the3“official”3name3of3the3drug
.3Each3drug3is3assigned3only3one3generic3name3selected3by3the3U.S.3Adopted3Name3Council,3and3the
3name3is3not3capitalized.3The3brand 3name3is3equivalent3to3the3trade3name3and3is3capitalized.3Althoug
h3the3brand3name3is3technically3the3name3of3the3company3marketing3the3product,3this3term3is3often3us
ed3interchangeably3with3the3trade3name.3The3code3name3is3the3initial3term3used3within3a3pharmaceuti
cal3company3to3refer3to3a3drug3while3it3is3undergoing3investigation3and3is3often3a3combination3of3cap
ital3letters3and3numbers,3the3letters3representing3an3abbreviation3of3the3company3name.
DIF: Comprehension
REF:3 Drug3Names3|3p.343OBJ:3 3
TOP:3 NBDHE,36.0.3Pharmacology
5. A3drug’s3generic3name3is3selected3by3the
a. pharmaceutical3company3manufacturing3it.
b. Food3and3Drug3Administration3(FDA).
c. U.S.3Adopted3Name3Council.
d. Federal3Patent3Office.
ANS:3 C
Each3drug3is3assigned3only3one3generic3name3(e.g.,3ibuprofen).3It3is3selected3by3the3U.S.3Adopted3Na
me3Council.3The3generic3name3is3not3selected3by3the3FDA3or3the3Federal3Patent3Office.3The3pharma
ceutical3company3manufacturing3the3drug3clearly3has3an3influence3on3the3generic3name3given3its3dru
g,3but3the3final3decision3is3not3the3company’s.
DIF: Recall REF:3 Drug3Names3|3p.34
OBJ:3 33TOP:3 NBDHE,36.0.3Pharmacology
6. Which3of3the3following3is3true3concerning3generic3and3trade3names3of3drugs?
a. A3drug3may3only3have3one3generic3name3and3one3trade3name
.
, b. A3drug3may3only3have3one3generic3name,3but3it3may3have3several3trade3name
s.
c. A3drug3may3have3several3generic3names,3but3it3may3only3have3one3trade3nam
e.
d. A3drug3may3have3several3generic3names3and3several3trade3names.
ANS:3 B
Each3drug3has3only3one3generic3name3but3may3have3several3trade3names.3For3each3drug,3there3is3only
3one3generic3name.3It3is3not3capitalized,3and3it3becomes3the3“official”3name3of3the3drug.3The3pharmac
eutical3company3discovering3the3drug3gives3the3drug3a3trade3name.3The3trade3name3is3protected3by3th
e3Federal3Patent3Law3for3203years3from3the3earliest3claimed3filing3date,3plus3patent3term3extensions.3
Although3the3brand3name3is3technically3the3name3of3the3company3marketing3the3product,3it3is3often3u
sed3interchangeably3with3the3trade3name.
DIF: Comprehension
REF:3 Drug3Names3|3p.343OBJ:3 3
TOP:3 NBDHE,36.0.3Pharmacology
7. Two3drugs3that3are3found3to3be3chemically3equivalent,3but3not3biologically3equivalent3
or3therapeutically3equivalent3are3said3to3differ3in
a. potency.
b. efficacy.
c. bioavailability.
d. therapeutic3index.
ANS:3 C
A3preparation3can3be3chemically3equivalent3yet3not3biologically3or3therapeutically3equivalent.3These3
products3are3said3to3differ3in3their3bioavailability.3The3potency3of3a3drug3is3a3function3of3the3amount3
of3drug3required3to3produce3an3effect.3The3efficacy3is3the3maximum3intensity3of3effect3or3response3th
at3can3be3produced3by3a3drug.3The3therapeutic3index3is3the3ratio3of3the3lethal3dose3for350%3of3the3ex
perimental3animals3divided3by3the3effective3dose3for350%3of3the3experimental3animals.3If3the3value3o
f3the3therapeutic3index3is3small,3toxicity3is3more3likely.
DIF: Recall
REF:3 Drug3Names3(Drug3Substitution)3|3p.353OBJ:3 4
TOP:3 NBDHE,36.0.3Pharmacology
8. How3many3years3must3pass3after3a3drug3patent3expires3before3other3drug3companies3can3market3t
he3same3compound3as3a3generic3drug?
a. 203years
b. 173years
c. 73years
d. 03years
ANS:3 D
Once3a3drug3patent3expires,3competing3companies3may3immediately3market3the3same3compound3in3g
eneric3form.3The3pharmaceutical3company3discovering3the3drug3gives3the3drug3a3trade3name.3The3tra
de3name3is3protected3by3the3Federal3Patent3Law3for3203years3from3the3earliest3claimed3filing3date,3pl
us3the3patent3term3extensions.
DIF: Application
REF:3 Drug3Names3(Drug3Substitution)3|3p.353OBJ:3 4
TOP:3 NBDHE,36.0.3Pharmacology
ting
Haveles:3Applied3Pharmacology3for3the3Dental3Hygienist,39th3Edition
MULTIPLE3CHOICE
1. Knowledge3of3pharmacology3aids3the3dental3professional3in
a. obtaining3a3patient’s3health3history.
b. administering3drugs3in3the3office.
c. handling3emergency3situations.
d. selection3of3a3nonprescription3medication.
e. All3of3the3above.
ANS:3 E
All3of3the3choices3are3true.3Because3many3of3our3patients3are3being3treated3with3drugs,3knowledge3of
3pharmacology3helps3in3understanding3and3interpreting3patients’3responses3to3health3history3questions
.3Knowledge3of3the3therapeutic3and3adverse3effects3of3medications3obviously3helps3in3their3proper3ad
ministration3in3the3office.3Emergency3situations3may3be3caused3by3drugs3or3treated3by3drugs;3thus,3k
nowledge3of3pharmacology3is3of3great3help,3especially3because3a3rapid3response3is3sometimes3requir
ed.3A3clear3understanding3of3the3concepts3of3drug3action,3drug3handling3by3the3body,3and3drug3intera
ctions3will3allow3the3dental3practitioner3to3make3proper3judgments3and3grasp3the3concepts3relevant3to
3new3drug3therapies3on3the3market.
DIF: Application
REF:3 Role3of3the3Dental3Hygienist3(Medication/Health3History),3Role3of3the3Dental3Hygienist3(Medicati
on3Administration),3Role3of3the3Dental3Hygienist3(Emergency3Situations),3Role3of3the3Dental3Hygienist3(
Nonprescription3Medication)3|3pp.32-3 OBJ: 1
TOP:3 NBDHE,36.0.3Pharmacology
2. Which3of3the3following3statements3is3true3regarding3planning3appointments?
a. Whether3or3not3patients3are3taking3medication3for3systemic3diseases3is3of3littl
e
consequence3in3the3dental3office.
b. Asthmatic3patients3should3have3dental3appointments3in3the3morning.
c. Diabetic3patients3usually3have3fewer3problems3with3a3morning3appointment 3c
ompared3with3afternoon3appointments.
d. Both3B3and3C3are3true.
ANS:3 D
Asthmatic3patients3who3experience3dental3anxiety3should3schedule3their3appointments3when3they3are3
not3rushed3or3under3pressure3early3in3the3morning.3Diabetic3patients3usually3have3relatively3fewer3pr
oblems3with3a3morning3appointment.3Patients3taking3medication3for3systemic3diseases3may3require3s
pecial3handling3in3the3dental3office.
DIF: Comprehension
REF:3 Role3of3the3Dental3Hygienist3(Appointment3Scheduling)3|3p.3
33OBJ:3 1 TOP:3 NBDHE,36.0.3Pharmacology
,3. Nutritional3or3herbal3supplements
a. carry3the3U.S.3Food3and3Drug3Administration3(FDA)3approval3for3disease3states
.
b. are3not3drugs.
c. can3cause3adverse3effects.
d. will3not3interact3with3other3drugs3the3patient3may3be3taking.
ANS:3 C
Nutritional3or3herbal3supplements3are3quite3capable3of3causing3adverse3effects.3The3majority3of3nutritio
nal3or3herbal3supplements3do3not3carry3FDA3approval3for3treating3disease3states.3These3supplements3ar
e3drugs3and3can3cause3adverse3effects3and3interact3with3different3drugs.
DIF: Comprehension
REF:3 Role3of3the3Dental3Hygienist3(Nutritional3or3Herbal3Supplements)3|3p.
333OBJ:3 1 TOP:3 NBDHE,36.0.3Pharmacology
4. Which3type3of3drug3name3usually3begins3with3a3lowercase3letter?
a. Brand3name
b. Code3name
c. Generic3name
d. Trade3name
ANS:3 C
Before3any3drug3is3marketed,3it3is3given3a3generic3name3that3becomes3the3“official”3name3of3the3drug
.3Each3drug3is3assigned3only3one3generic3name3selected3by3the3U.S.3Adopted3Name3Council,3and3the
3name3is3not3capitalized.3The3brand 3name3is3equivalent3to3the3trade3name3and3is3capitalized.3Althoug
h3the3brand3name3is3technically3the3name3of3the3company3marketing3the3product,3this3term3is3often3us
ed3interchangeably3with3the3trade3name.3The3code3name3is3the3initial3term3used3within3a3pharmaceuti
cal3company3to3refer3to3a3drug3while3it3is3undergoing3investigation3and3is3often3a3combination3of3cap
ital3letters3and3numbers,3the3letters3representing3an3abbreviation3of3the3company3name.
DIF: Comprehension
REF:3 Drug3Names3|3p.343OBJ:3 3
TOP:3 NBDHE,36.0.3Pharmacology
5. A3drug’s3generic3name3is3selected3by3the
a. pharmaceutical3company3manufacturing3it.
b. Food3and3Drug3Administration3(FDA).
c. U.S.3Adopted3Name3Council.
d. Federal3Patent3Office.
ANS:3 C
Each3drug3is3assigned3only3one3generic3name3(e.g.,3ibuprofen).3It3is3selected3by3the3U.S.3Adopted3Na
me3Council.3The3generic3name3is3not3selected3by3the3FDA3or3the3Federal3Patent3Office.3The3pharma
ceutical3company3manufacturing3the3drug3clearly3has3an3influence3on3the3generic3name3given3its3dru
g,3but3the3final3decision3is3not3the3company’s.
DIF: Recall REF:3 Drug3Names3|3p.34
OBJ:3 33TOP:3 NBDHE,36.0.3Pharmacology
6. Which3of3the3following3is3true3concerning3generic3and3trade3names3of3drugs?
a. A3drug3may3only3have3one3generic3name3and3one3trade3name
.
, b. A3drug3may3only3have3one3generic3name,3but3it3may3have3several3trade3name
s.
c. A3drug3may3have3several3generic3names,3but3it3may3only3have3one3trade3nam
e.
d. A3drug3may3have3several3generic3names3and3several3trade3names.
ANS:3 B
Each3drug3has3only3one3generic3name3but3may3have3several3trade3names.3For3each3drug,3there3is3only
3one3generic3name.3It3is3not3capitalized,3and3it3becomes3the3“official”3name3of3the3drug.3The3pharmac
eutical3company3discovering3the3drug3gives3the3drug3a3trade3name.3The3trade3name3is3protected3by3th
e3Federal3Patent3Law3for3203years3from3the3earliest3claimed3filing3date,3plus3patent3term3extensions.3
Although3the3brand3name3is3technically3the3name3of3the3company3marketing3the3product,3it3is3often3u
sed3interchangeably3with3the3trade3name.
DIF: Comprehension
REF:3 Drug3Names3|3p.343OBJ:3 3
TOP:3 NBDHE,36.0.3Pharmacology
7. Two3drugs3that3are3found3to3be3chemically3equivalent,3but3not3biologically3equivalent3
or3therapeutically3equivalent3are3said3to3differ3in
a. potency.
b. efficacy.
c. bioavailability.
d. therapeutic3index.
ANS:3 C
A3preparation3can3be3chemically3equivalent3yet3not3biologically3or3therapeutically3equivalent.3These3
products3are3said3to3differ3in3their3bioavailability.3The3potency3of3a3drug3is3a3function3of3the3amount3
of3drug3required3to3produce3an3effect.3The3efficacy3is3the3maximum3intensity3of3effect3or3response3th
at3can3be3produced3by3a3drug.3The3therapeutic3index3is3the3ratio3of3the3lethal3dose3for350%3of3the3ex
perimental3animals3divided3by3the3effective3dose3for350%3of3the3experimental3animals.3If3the3value3o
f3the3therapeutic3index3is3small,3toxicity3is3more3likely.
DIF: Recall
REF:3 Drug3Names3(Drug3Substitution)3|3p.353OBJ:3 4
TOP:3 NBDHE,36.0.3Pharmacology
8. How3many3years3must3pass3after3a3drug3patent3expires3before3other3drug3companies3can3market3t
he3same3compound3as3a3generic3drug?
a. 203years
b. 173years
c. 73years
d. 03years
ANS:3 D
Once3a3drug3patent3expires,3competing3companies3may3immediately3market3the3same3compound3in3g
eneric3form.3The3pharmaceutical3company3discovering3the3drug3gives3the3drug3a3trade3name.3The3tra
de3name3is3protected3by3the3Federal3Patent3Law3for3203years3from3the3earliest3claimed3filing3date,3pl
us3the3patent3term3extensions.
DIF: Application
REF:3 Drug3Names3(Drug3Substitution)3|3p.353OBJ:3 4
TOP:3 NBDHE,36.0.3Pharmacology